Nanjing Edcheng Ningxin Pharmaceutical Research and Development Co., Ltd.

Primary objective To evaluate the overall survival (OS) efficacy of AL8326 tablets as a single agent in patients with small cell lung cancer who have relapsed or progressed after second-line or higher systemic treatment. Secondary objective To evaluate the progression-free survival (PFS) and other efficacy indicators of AL8326 tablets as a single agent in patients with small cell lung cancer who have relapsed or progressed after second-line or higher systemic treatment.

Primary objective To evaluate the preliminary efficacy of AL2846 capsules in patients with iodine-refractory differentiated thyroid cancer who have failed previous TKI treatment. Secondary objective To evaluate the safety of AL2846 capsules in patients with iodine-refractory differentiated thyroid cancer who have failed previous TKI treatment.

[Primary purpose] To evaluate the efficacy of AL2846 capsules in subjects with previously treated advanced solid tumors; [Secondary purpose] To evaluate the safety of AL2846 capsules in subjects with previously treated advanced solid tumors; To evaluate the pharmacokinetic characteristics of AL2846 capsules in subjects with previously treated advanced solid tumors.